5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Senores Pharmaceuticals Ltd.

•
senorespharma.comBSE: 544319NSE: SENORES
Market Cap₹ 6,597 Cr.
Current Price
High / Low₹ 1,599 / 662
Stock P/E354.9
Book Value₹ 163
Price to Book4.66
Dividend Yield0.00 %
ROCE4.2 %
ROE2.8 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Working capital cycle has improved - days down from 3513 to 640
  • Institutional investors have been accumulating - FII+DII up 3.2pp

CONS

  • Company is loss-making at the operating / net level
  • A large part of profit comes from other income (241.6% of PBT)
  • Operating cash flow has been negative in recent years
  • Recent results are weak - TTM profit is down 26.8% versus prior year
  • Company has a low return on capital employed of 3.0%
  • Company has a low return on equity of 1.5% over last 3 years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1904.0037.77456833.380.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9245.0083.91245425.700.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4924.7085.89187319.760.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1135.0025.09113216.680.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1389.0033.29112211.540.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1872.1592.52101154.550.11362.07123.942026.3129.1018.2031.50
7.LUPIN2135.0017.6697626.260.841416.9816.018276.8934.2828.8629.59
8.MANKIND2345.0047.4296859.070.04574.0929.124030.5912.8913.2426.30
9.DRREDDY1155.0029.9296405.530.69435.60-69.108099.80-5.2113.7510.63
10.AUROPHARMA1627.0025.2293613.980.251032.0325.229150.3517.4412.7620.54
11.GLENMARK2458.8038.6069393.400.10482.83927.884018.4831.3520.3520.03
12.SENORES1432.4552.206596.950.0030.4543.77180.2138.3015.6629.83
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
91171010121521173727
9981112152134304035
Operating Profit-12-1-1-2-3-5-13-13-3-8
OPM %-5.95%17.72%-10.43%-13.91%-25.23%-23.02%-35.44%-61.57%-79.61%-9.45%-30.23%
252379811102210
Interest11113222222
Depreciation01111124444
Profit before Tax060113484131
Tax %59.18%158.83%11.43%44.44%18.94%30.34%24.79%16.06%24.72%33.18%25.90%
Net Profit0-3001236381
0.08-1.050.090.090.320.390.591.401.981.840.22

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
14123439106101
12143446125139
Operating Profit1-2-0-7-19-38
OPM %8.54%-14.38%-0.21%-18.89%-17.61%-37.21%
177226653
Interest123777
Depreciation11231315
Profit before Tax12252725
Tax %18.24%38.23%60.10%27.79%26.26%26.41%
Net Profit11142019
EPS1.240.950.270.804.40—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
—
3 Years:
105%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
157%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
103%

RETURN ON EQUITY

10 Years:
—
5 Years:
2%
3 Years:
1%
Last Year:
3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

No bonus data found

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital910314646
2529138662704
1556999382
Trade Payables64121331
01272024
Total Liabilities55112286834886
28245598
Capital Work in Progress0815349
12882104154
335910
00222676
Cash & Bank1010360146
3784128247393
Total Assets55112286834886

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
-24-43-19-20-27
Cash from Investing-10-5-57-436-19
Cash from Financing344787533-3
-0-21076-49

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
PER SHARE
EPS (₹)0.781.220.270.804.40
Book Value (₹)38.5439.6655.10153.74162.78
Dividend per Share (₹)0.000.000.000.000.00
Cash EPS (₹)1.592.170.931.477.27
PROFITABILITY
Operating Margin %15.47%40.48%-0.21%-18.89%-17.61%
Net Margin %5.03%9.68%2.38%9.57%19.09%
ROE %2.02%3.30%0.78%0.84%2.78%
ROCE %2.90%5.54%2.63%2.19%4.24%
1.25%1.44%0.41%0.66%2.35%
EFFICIENCY
Debtor Days226355202226176
Inventory Days8090416232
Payable Days269325151253149
37120923559
FINANCIAL HEALTH
Debt to Equity (x)0.42x1.55x0.55x0.13x0.10x
Interest Coverage (x)2.50x1.91x1.75x1.78x4.93x
1.59x0.59x0.44x9.99x3.67x
GROWTH
Revenue Growth %0.00%-8.58%174.67%13.32%175.27%
Operating Profit Growth %0.00%139.22%35.28%116.96%224.07%
Net Profit Growth %0.00%75.86%-32.44%355.56%448.78%
0.00%0.00%-78.27%201.81%448.78%
VALUATION
P/E (x)0.00x0.00x0.00x714.78x172.35x
P/B (x)0.00x0.00x0.00x3.73x4.66x
Dividend Yield %0.00%0.00%0.00%0.00%0.00%
0.00x0.00x16.64x161.23x71.65x

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
45.7645.7645.7745.7845.8045.8045.8245.82
5.524.244.173.664.283.353.646.62
16.6111.499.669.518.629.329.629.77
Government0.000.000.000.000.000.000.000.00
32.1138.4840.4041.0441.3141.5440.9337.79

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04
Copy of Newspaper Publication

2026-09-04 - Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the Company.

2026-09-03
Shareholders meeting

2026-09-03 - Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-27
Copy of Newspaper Publication

2026-08-27 - Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company

2026-08-26
Appointment

2026-08-26 - Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Viranchi Arvindbhai Shah as Non- Executive Independent Director of the company w.e.f. August 26, 2026.

2026-08-26
General Updates

2026-08-26 - Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 ( ESOS 2026 / SCHEME )

2026-08-26
General Updates

2026-08-26 - Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico

2026-08-26
General Updates

2026-08-26 - Proposed incorporation of a Subsidiary Company in Canada

2026-08-26
Outcome of Board Meeting

2026-08-26 - Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.

News

Recent coverage and analyst commentary for SENORES

Loading news…

🤖

AI Stock Analyst

Senores Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login